Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients with Relapsed or Refractory CLL, MM, or AML

NCT04887259 is registered in ClinicalTrials.gov with Lava Therapeutics as lead sponsor.

NCT NCT04887259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of LAVA-051 in Patients with Relapsed or Refractory CLL, MM, or AML
Lead sponsor
Lava Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
July 12, 2021
Completion date
September 6, 2023
Enrollment
16 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma